Time to blood culture positivity an independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia
Soline Simeon, Vincent Le Moing, Sarah Tubiana, Xavier Duval, Damien Fournier, Jean-Philippe Lavigne, Marie-Line Erpelding, Claude-Alexandre Gustave, Stephanie Desage, Catherine Chirouze, et al.

To cite this version:

HAL Id: hal-02561894
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02561894v2
Submitted on 12 Sep 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Time to blood culture positivity: an independent predictor of infective endocarditis and mortality in patients with *Staphylococcus aureus* bacteraemia

Soline Siméon,¹ Vincent Le Moing,² Sarah Tubiana,³-⁵ Xavier Duval,³-⁵ Damien Fournier,⁶ Jean-Philippe Lavigne,⁷,⁸ Marie-Line Erpelding,⁹ Claude-Alexandre Gustave,¹⁰ Stephanie Desage,¹¹ Catherine Chirouze,¹² François Vandenesch,¹⁰ Pierre Tattevin,¹,¹³ and the VIRSTA/AEPEI Study Group.

¹Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, CHU Rennes, France;
²Maladies Infectieuses, CHU de Montpellier, France;
³INSERM CIC-1425, AP-HP, Hôpital Bichat Claude Bernard, Paris, France;
⁴INSERM, IAME, UMR 1137, Paris, France;
⁵Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France;
⁶Laboratoire de Bactériologie, CHRU Besançon, France;
⁷Service de Microbiologie, CHU Caremeau, Nîmes, France;
⁸INSERM, U1047, Université de Montpellier, Nîmes, France;
⁹INSERM, CHRU Nancy, Université de Lorraine, CIC-1433 Epidemiologie Clinique, Nancy, France;
¹⁰Centre National de Référence des Staphylocoques, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France;
Laboratoire de bactériologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France;

UMR CNRS 6249, Université de Bourgogne-Franche Comté – Service de maladies infectieuses et tropicales, CHRU de Besançon, France;

INSERM U1230, Université Rennes-I, Rennes, France

Corresponding author: Pierre Tattevin, Service des Maladies Infectieuses et de Réanimation Médicale, CHU Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes Cedex, France. Tel +33 299289564; fax +33 299282452, E-mail address: pierre.tattevin@chu-rennes.fr
ABSTRACT

Objectives: Time to blood culture positivity (TTP), a routinely available parameter in automated blood culture systems, may be a proxy for infectious burden in patients with bloodstream infections. We aimed to study the association between TTP and infective endocarditis (IE), or death, in patients with Staphylococcus aureus bacteraemia.

Methods: VIRSTA is a multicenter prospective cohort study that included all adult patients with S. aureus bacteraemia in eight university hospitals in France (2009-2011). We analyzed data from four centers which collected data on TTP. Regression models were used to study the association between TTP and definite IE (Duke-Li criteria), and 30 day-mortality.

Results: We included 587 patients with S. aureus bacteraemia: mean age was 65.3±16.3 years, 420/587 patients (71.6%) were male, 121/587 (20.6%) died, and 42/587 (7.2%) had definite IE. Median TTP of first positive blood culture was 13.7 h (interquartile range, 9.9-18). On multivariate analysis, 30-day mortality was associated with TTP≤13.7 h (74/295 (25.1%) vs 47/292 (16.1%), P=0.02), as well as old age, McCabe score, methicillin resistance, stroke, pneumonia, and C-Reactive Protein. TTP was also independently associated with IE, but with a U-shape curve: IE was more common in the first (TTP<10 h, 17/148, 11.5%), and the last (TTP>18 h, 8/146, 5.5%) quartiles of TTP, P=0.002.

Conclusions: TTP provides reliable information in patients with S. aureus bacteraemia, on the risk of IE, and prognosis, with short TTP being an independent predictor of death. This data readily available at no cost may be used to identify patients who require specific attention.

KEY WORDS: time to blood culture positivity; Staphylococcus aureus; bacteraemia; mortality; infective endocarditis
Introduction

*Staphylococcus aureus* bacteraemia (SAB) is a public health issue, with an incidence estimated at 15-40 per 100 000 person-years (1,2), and in-hospital mortality rates of 15-25% (3–5). Age, sepsis, comorbidities, methicillin-resistant *S. aureus* (MRSA), and inadequate antibiotic therapy are the main prognostic factors (3,6,7). In addition, *S. aureus* is the most prevalent microorganism causing infective endocarditis (IE) (8,9), a major complication of SAB (10,11).

Time to positivity of blood cultures (TTP) is defined as the time from the start of incubation to alert signal, in automated blood culture systems. TTP may provide useful information, since a short TTP may reflect high blood bacterial load, and/or enhanced virulence. This property has already been harnessed to diagnose catheter-related bloodstream infections based on differential TTP of paired blood cultures sampled from venipuncture and the catheter (12–14). However, this parameter, available at no cost with most automated blood culture systems, is rarely mentioned as a tool to adjust the management of patients with positive blood cultures.

A few studies evaluated the association between TTP and mortality in SAB (15–17), or IE (18), but they were limited by small sample size, retrospective and/or monocentre design, and found discordant results. We aimed to evaluate the association between TTP and i) IE, ii) mortality, in a prospective cohort of adult patients with SAB.

Methods

Population

The VIRSTA prospective cohort study included all consecutive adult patients with SAB between April 2009 and October 2011 in 8 tertiary-care university hospitals in France.
Trained research assistants collected clinical, biological, therapeutic data, and
outcome. All patients, their relatives, or physicians, were contacted 12 weeks after the
beginning of SAB to check if patients were alive, and the date of death in patients who died.
The diagnosis of definite IE according to modified Duke criteria (21) was verified by a local
adjudication committee including at least one cardiologist, one infectious diseases physician,
and one bacteriologist. This ancillary study was restricted to the four VIRSTA sites where
blood culture bottles were placed in automated blood culture instruments upon receipt in
laboratory, 24/24 hours, 7/7 days, and TTP was routinely collected during the study period.

Definitions
SAB was defined as the isolation of \textit{S. aureus} from at least one blood culture bottle
sampled by venipuncture. For each patient, only TTP of the first set of positive blood cultures
was retained for analysis. When both aerobic and anaerobic bottles were positive, we used the
shortest TTP. SAB was classified as nosocomial, healthcare-associated, or community-onset
using validated criteria (22). McCabe score classified patients in 4 categories (23): 1, no
underlying disease; 2, non-fatal underlying disease; 3, ultimately fatal underlying disease
(within 5 years); and 4, rapidly fatal underlying disease (within one year).

Microbiological methods
In each center, approximately 10 mL of blood was inoculated into aerobic and
anaerobic bottles by nurses using a standardized sterile technique (24). The BACTEC®
system (Becton Dickinson) was used in three sites, and BacT/Alert® (bioMérieux) in one.
TTP was defined as the time from the start of incubation to alert signal, as previously (12–14).
Antimicrobial susceptibility testing was performed per guidelines of the CASFM-EUCAST
(www.sfm-microbiologie.org). Strains isolated from patients with IE were centralized at the French National Reference Center for Staphylococci.

To study the mechanisms behind short, and long TTP, we performed in-depth analysis of a subset of 13 isolates from IE patients with the shortest, and the longest quartiles of TTP. Firstly, we estimated the crude doubling time: each strain was adjusted to an OD600nm = 0.5, and 100 µL of a 1/100 dilution in BHI was inoculated in triplicate into 96-wells plates that were incubated for 24 hours at 37°C with continuous OD600nm monitoring (Tecan Infinite® 200 PRO). Doubling times were calculated from the exponential growth phase data by Growthrate® 2.1. Secondly, to mimic the conditions encountered in blood culture bottles and measure the TTP of a standardized inoculum, each strain was adjusted to an OD600nm = 2 in 0.9% NaCl solution, and this suspension was diluted to achieve a concentration of 60 CFU/mL of \textit{S. aureus}. One mL of this suspension was added to aerobic and anaerobic blood culture bottles (bioMérieux, 3 pairs per strain), previously inoculated with 5 mL of whole human blood. Blood cultures bottles were then incubated in an automated blood culture instrument (Virtuo®, bioMérieux) in which TTP was recorded as in routine clinical laboratory conditions. Once detected positive, a Gram stain and a Maldi-Tof identification (Vitek MS, bioMérieux) were performed. Lastly, genotyping of isolates was performed with diagnostic DNA microarrays, \textit{S. aureus} Genotyping kit 2.0 (Alere, Jena, Germany) (25). The assignment of isolates to clonal complexes (CCs) was performed by comparing hybridization profiles to multi-locus sequence typing (MLST) reference strains.

\textit{Statistical analysis}

Non-normally distributed continuous variables were reported as median with interquartile range (IQR). Normally distributed continuous variables were reported as mean with standard deviation. Qualitative variables were expressed as number and proportions.
Continuous variables were compared using Student’s $t$-test for normally distributed and the Wilcoxon-Mann-Whitney nonparametric test for non-normally distributed variables. Differences in proportions were compared by a chi-square or a Fisher's exact test, when appropriate. We performed a bivariate analysis to compare SAB with short (<median), and long (>median) TTP. A logistic regression model was developed to study factors associated with IE, excluding major Duke criteria in the final model. A Poisson regression model was used to assess factors associated with 30-day mortality. In regression models, continuous variables were modeled using fractional polynomial if relationship was nonlinear (26). Risk was expressed as relative risk (RR) for Poisson regression, and odds ratio (OR) for logistic regression with 95% confidence intervals (CI).

First, regression analyses adjusted to age, sex and centre were undertaken to quantify the relationships between the explanatory covariates and the response variables ‘IE’ or ‘dead at day 30’. Time to positivity, sex, age, centre and covariates with $P<0.2$ level in previous analyses were entered into logistic and Poisson multivariate regression models. Manual backward stepwise variable elimination was then performed to determine final multivariate models. We found no interaction between TTP and sex, and between TTP and methicillin-resistance in models. Goodness-of-fit was checked for each model by the Pearson, Hosmer-Lemeshow, and receiver operating characteristic curve tests. $P <0.05$ was considered as statistically significant in two-tailed. Analyses were performed using Stata software (version 12.0, Stata Corporation).

Ethics

VIRSTA study was approved by Sud-Méditerranée IV Protection to Persons Committee, and registered in the European Clinical Trials Database (EUDRACT) under the number 2008-A00680-55.
Results

Patient characteristics

Of the 2,008 patients enrolled in the VIRSTA cohort, data on TTP was prospectively collected in 587 (i.e., those admitted in the four sites where TTP was routinely collected during the study period, with immediate transfer of blood cultures samples to the laboratory for incubation, 24/24 hours, 7/7 days, see flowchart, web-only Supplementary Figure 1). Patients characteristics are summarized in Table 1. As compared to the rest of the VIRSTA cohort, these patients had a lower rate of IE: 42/587 (7.2%), vs 179/1421 (12.6%), \(P<0.0001\), web-only Supplementary Table 1. Blood cultures were positive in both aerobic and anaerobic bottles for 423/587 patients (72.1%), only in aerobic bottles for 97/587 (16.5%), and only in anaerobic bottles for 67/587 (11.4%).

Factors associated with short TTP (Figure 1A)

The median TTP was 13.7 (IQR, 9.9-18) hours, with no significant difference in TTP distribution between the two automated blood culture systems. In univariate analyses, factors associated with short TTP (\(<13.7\) h) were renal failure, immunodepression, McCabe score of 4, central venous catheter, IE, stroke, emboli, and MSSA (web-only, Supplementary Table 2). The median TTP was 13 (IQR, 9.5-18) hours for MSSA, and 15 (IQR, 10.6-18) hours for MRSA \((P=0.14)\).

Association between TTP and IE (Figure 1B)

The relationship between TTP and IE was not linear, with a U-shape curve (Figure 2). Hence, we used fractional polynomials to describe the relationship between TTP, and IE. In univariate analysis, centre, community-acquired SAB, prosthetic valve, emboli, stroke,
osteitis, C reactive protein, and extreme quartiles of TTP (i.e. quartile 1, and 4), were associated with IE (Table 2). In multivariate analysis, centre, stroke, prosthetic valve, C reactive protein, TTP <10 h (quartile 1, OR 2.84 [1.33-6.10]), and TTP >18 h (quartile 4, OR 3.07 [0.99-9.45]) were independently associated with IE (Table 2). When we restricted the analyzes to the 393 patients who underwent echocardiography (either TTE, or TEE), we found similar findings, with a U-shape curve.

**Factors associated with 30-day mortality**

Old age, a McCabe score of 4, underlying liver disease, stroke, pneumonia, mitral vegetation, MRSA, and TTP <13.7 h were associated with mortality, whereas surgical site infection was associated with survival (Table 3). In multivariate analysis, TTP <13.7 h (RR 1.69, 95%CI 1.11-2.57), old age, McCabe score of 4, MRSA, stroke, pneumonia, and high C reactive protein were independently associated with 30-day mortality.

**Microbiological study of selected strains originating from patients with IE and extreme TTP**

Crude doubling time of *S. aureus* strains with short (<10 h, n=8) and long (>18 h, n=5) TTP were not different (Figure 3A). The two groups of isolates (short, and long TTP during the clinical study), had similar TTP in blood culture bottles inoculated with standardized inocula (*P*=0.9433, Figure 3B). All strains tested were methicillin susceptible, and no specific clonal complex was associated with either short or long TTP (Supplementary Table 2).

**Discussion**

In this prospective cohort of 587 patients with SAB, TTP of first positive blood culture was independently associated with IE, and 30-day mortality. Indeed, the prevalence of IE was
higher both in patients with short (quartile 1, <10 h), and long (quartile 4, >18 h) TTP, with a U-shape curve. Thirty-day mortality was 74/294 (25.2%) in patients with TTP <13.7 h (median), versus 47/292 (16.0%) in patients with TTP ≥13.7 h (P=0.03), and this association persisted after adjustment for other risk factors.

Significant differences were observed between patients enrolled in this ancillary study, and the rest of the VIRSTA cohort. However, our population was in line with most recent studies of SAB in adult patients, in terms of age (mean, 60-70 years), sex ratio (65-75% of males), major comorbidities (predominantly diabetes, cancer, and renal disease, >25% each), and outcome (30 day-mortality, 15-25%) (4,27). In addition, predictors of mortality were similar to those previously described: age, McCabe score, MRSA, pneumonia or C reactive protein (28,29). Of note, the automated blood culture systems in use during the study period, BACTEC®, and BacT/Alert®, are by far the most commonly used worldwide, and TTP distribution (median, 13.7 hours; IQR, 9.9-18) is in line with previous studies of TTP in SAB (15,16). This suggests that our findings may apply to most settings where automated blood culture systems are in use.

The relationship between TTP and IE is poorly documented. In a cohort of 312 patients with SAB (18), TTP was shorter for IE (12.1±4.0 h, P=0.002), and catheter-related infections (15.1±5.3 h, P=0.004), and longer for bone (20.6±9.5 h, P=0.04), and respiratory tract infections (24.8±15.3 h, P=0.001). In our study, extreme quartiles (TTP ≤10 h, and TTP >18 h), were independently associated with higher risk of IE. We speculated that this biphasic behavior could reflect two unrelated biological phenomenon: i) SAB with high inoculum (hence, short TTP), could be at higher risk of IE; ii) once IE has developed, bacteria enter in a slow metabolic state within vegetations (30,31), which may be responsible for longer TTP when these bacteria seed the circulation and are inoculated in blood culture bottles. However, doubling time of isolates from IE patients with shortest, or longest TTP, were not different in
vitro, and blood culture bottles inoculated with a standardized quantity of *S. aureus* from these two groups had similar TTP. This suggests that differences in TTP reflect differences in the quantity of bacteria inoculated in blood culture bottles – and thus differences in bacterial concentration in circulating patient blood, rather than intrinsic characteristics of the isolates. This U-shape curve may also have reflected two pathophysiological models for IE: cases with shorter TTP, and thus high bacterial load, corresponding to rapidly progressive IE caused by virulent strains, whilst extended TTP could result from less virulent bacteria and/or better control by the host. However, IE cases with shortest (quartile 1), and longest (quartile 4) TTP were similar in terms of duration of symptoms before diagnosis, clinical presentation, and immunosuppression (data not shown). To our knowledge, increased risk of IE in patients with long TTP has never been reported. Hence, confirmatory studies on the association between TTP and IE are required.

We conducted a medline search to identify studies that investigated TTP in patients with SAB. We found 6 studies (15–18,32,33). TTP ≤12 h has been associated with increased in-hospital mortality (25.0%, versus 4.3% if TTP>12 h, *P*=0.006) (32), and increased 30-day mortality (OR 5.91, CI95% 1.80-19.44; *P*=0.003) (15), in two distinct cohorts of SAB. TTP ≤14 h was an independent predictor of SAB-related mortality in another study (18). Two recent studies did not confirm this association: a retrospective analysis of 684 adult and pediatric SAB (MSSA and MRSA), found that TTP >48 h was associated with higher 30-day mortality as compared to TTP <12 h (33). However, children and adults have different bacterial load during bacteremia (34), so that the merging of pediatric and adult population may not be appropriate. TTP was not associated with mortality in another cohort of 87 SAB (17). Interestingly, this latter study and another found that a TTP ratio of <1.5 between the first and the second positive blood culture in patients on appropriate antibacterial treatment was an independent risk factor for new infectious focus, and death (17,34). Accordingly,
failure to increase TTP by at least 50% in sequential blood cultures should prompt reinforcement of anti-staphylococcal regimen, and/or extraction of foreign devices or surgical intervention when appropriate.

Our study has limitations: only 587 patients of the VIRSTA cohort could be enrolled, with significant differences with the rest of the cohort. Among them, only 393 (67.0%) underwent echocardiography, of whom 42 fulfilled criteria for definite IE. Hence, analyses of risk factors for IE were limited by small sample size. Secondly, two different blood culture instruments were used during the study period. Finally, we did not monitor the volume of blood inoculated into blood culture bottles, although this parameter has a strong impact on pathogen detection, and TTP (24). Of note, short TTP implies that physicians in charge were informed earlier that their patients had SAB. Theoretically, this opportunity for earlier appropriate treatment may underestimate the prognostic value of short TTP. Strengths of our study include its design (prospective, multicenter, observational, with consecutive enrolment of all adult patients with SAB), which reduces the risk of selection bias. Many variables were prospectively collected, with a low rate of missing data, which enabled to consider a large range of potential confounding factors. To our knowledge, this is the largest study on TTP in SAB to date. Lastly, echocardiography was performed in 393/587 (67.0%) of SAB cases. Although a 100% rate would be preferrable, 67.0% is, to our knowledge, the highest rate of echocardiography across all observational SAB studies currently available.

In conclusion, results of our study advocate for the development of clinical use of TTP in the management of patients with SAB. Those with short TTP should be monitored more closely, and treated more aggressively, as they belong to a group at higher risk of early death. Echocardiography has a higher yield in this group.
Transparency declaration. All authors: No reported conflict of interest. The study was founded by the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2008). French national network on IE/ AEPEI which participated in the study is supported by the Institut National de la Santé et de la Recherche Médicale (Inserm).

The VIRSTA/AEPEI Study Group:


Coordination and statistical analyses: François Alla, Pierre Braquet, Marie-Line Erpelding, Laetitia Minary, Sarah Tubiana.

Centre National de Référence des staphylocoques: Michèle Bès, Jérôme Etienne, Taïssia Lelekov-Boissard, Anne Tristan, François Vandenesch.
Erasmus University Rotterdam: Alex Van Belkum, Fernando Rivadeneira, Willem Vanwamel.

Sponsor CHU de Montpellier: Sandrine Barbas, Christine Delonca, Virginie Sussmuth, Anne Verchère.
Table 1. Study population (n=587)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>65.3 ± 16.3</td>
</tr>
<tr>
<td>Male</td>
<td>420 (71.6)</td>
</tr>
<tr>
<td>Centre</td>
<td></td>
</tr>
<tr>
<td>Besançon</td>
<td>106 (18.1)</td>
</tr>
<tr>
<td>Lyon</td>
<td>301 (51.3)</td>
</tr>
<tr>
<td>Nîmes</td>
<td>40 (6.8)</td>
</tr>
<tr>
<td>Paris-Bichat</td>
<td>140 (23.8)</td>
</tr>
<tr>
<td><strong>Co-morbid conditions</strong></td>
<td></td>
</tr>
<tr>
<td>Renal failure</td>
<td>153 (26.1)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>184 (31.4)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>120 (20.4)</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>17 (2.9)</td>
</tr>
<tr>
<td>Solid cancer</td>
<td>174 (29.6)</td>
</tr>
<tr>
<td>Immunocompromised status</td>
<td>123 (21.0)</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>107 (18.2)</td>
</tr>
<tr>
<td>McCabe score (n=584)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>58 (9.9)</td>
</tr>
<tr>
<td>2</td>
<td>232 (39.7)</td>
</tr>
<tr>
<td>3</td>
<td>200 (34.2)</td>
</tr>
<tr>
<td>4</td>
<td>94 (16.1)</td>
</tr>
<tr>
<td><strong>Presumed place of acquisition</strong> (n=563)</td>
<td></td>
</tr>
<tr>
<td>Community-acquired</td>
<td>166 (29.5)</td>
</tr>
<tr>
<td>Healthcare-associated</td>
<td>93 (16.5)</td>
</tr>
<tr>
<td>Nosocomial</td>
<td>304 (54.0)</td>
</tr>
<tr>
<td><strong>Site of infection</strong></td>
<td></td>
</tr>
<tr>
<td>Infective endocarditis</td>
<td>42 (7.2)</td>
</tr>
<tr>
<td>Osteitis (n=555)</td>
<td>62 (11.2)</td>
</tr>
<tr>
<td>Arthritis (n=554)</td>
<td>63 (11.4)</td>
</tr>
<tr>
<td>Pneumonia (n=540)</td>
<td>73 (13.5)</td>
</tr>
<tr>
<td>Skin and skin structure infection (n=555)</td>
<td>186 (33.5)</td>
</tr>
<tr>
<td>Urinary tract infection (n=554)</td>
<td>80 (14.4)</td>
</tr>
<tr>
<td>Catheter related-infection (n=565)</td>
<td>173 (30.6)</td>
</tr>
<tr>
<td><strong>Devices</strong></td>
<td></td>
</tr>
<tr>
<td>Pacemaker</td>
<td>39 (6.6)</td>
</tr>
<tr>
<td>Prosthetic valve</td>
<td>38 (6.5)</td>
</tr>
<tr>
<td>Vascular grafts</td>
<td>43 (7.3)</td>
</tr>
</tbody>
</table>
Variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prosthetic joint</td>
<td>73 (12.4)</td>
</tr>
</tbody>
</table>

Clinical features

<table>
<thead>
<tr>
<th>Feature</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>484 (82.4)</td>
</tr>
<tr>
<td>Heart valve disease (n=525)</td>
<td>125 (23.8)</td>
</tr>
<tr>
<td>Stroke (n=554)</td>
<td>18 (3.2)</td>
</tr>
<tr>
<td>Embolus</td>
<td>15 (2.6)</td>
</tr>
<tr>
<td>Intensive care unit</td>
<td>165 (28.1)</td>
</tr>
<tr>
<td>All-cause death</td>
<td>156 (26.6)</td>
</tr>
<tr>
<td>All-cause death at day 30</td>
<td>121 (20.6)</td>
</tr>
</tbody>
</table>

Biological parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Count (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C reactive protein (mg/L) (n=534)</td>
<td>182 (104-284)</td>
</tr>
<tr>
<td>Time to positivity (hours)</td>
<td>13.7 (9.9-18)</td>
</tr>
<tr>
<td>MRSA (n=585)</td>
<td>112 (19.2)</td>
</tr>
<tr>
<td>Antibiotic therapy before first blood culture (n=577)</td>
<td>38 (6.5)</td>
</tr>
</tbody>
</table>

Echocardiographic data

<table>
<thead>
<tr>
<th>Method</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTE</td>
<td>364 (62.0)</td>
</tr>
<tr>
<td>TEE</td>
<td>154 (26.2)</td>
</tr>
<tr>
<td>TTE and/or TEE</td>
<td>393 (67.0)</td>
</tr>
<tr>
<td>Vegetation (n=393)</td>
<td>31 (7.9)</td>
</tr>
</tbody>
</table>

Categorical variables are presented as numbers (%). Non-normally distributed quantitative variables are reported as median (quartile 1 - quartile 3). Normally distributed quantitative variables are presented as mean ± standard deviation. MRSA: Methicillin-resistant *Staphylococcus aureus*; TTE: transthoracic echocardiography; TEE: transesophageal echocardiography; Immunocompromised status: HIV, hematologic malignancy, immunosuppressive drugs
Table 2. Risk factors for infective endocarditis in patients with *S. aureus* bacteraemia

<table>
<thead>
<tr>
<th>Variables</th>
<th>Definite IE (n=42)</th>
<th>Others (n=545)</th>
<th>Univariate analysis</th>
<th>Multivariate analysis (n=477)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>P</td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, per year</td>
<td>64 (55–74)</td>
<td>67 (56–78)</td>
<td>0.98 (0.96–1.01)</td>
<td>0.10</td>
</tr>
<tr>
<td>Female</td>
<td>11 (26.2)</td>
<td>156 (28.6)</td>
<td>1.22 (0.82–1.84)</td>
<td>0.61</td>
</tr>
<tr>
<td>Centre</td>
<td>0.003</td>
<td>1</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Lyon</td>
<td>14 (4.7)</td>
<td>287 (95.3)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Besançon</td>
<td>4 (3.8)</td>
<td>102 (96.2)</td>
<td>0.81 (0.26–2.52)</td>
<td>0.54 (0.12–2.27)</td>
</tr>
<tr>
<td>Nîmes</td>
<td>6 (15.0)</td>
<td>34 (85.0)</td>
<td>4.13 (1.46–11.68)</td>
<td>3.27 (0.81–13.23)</td>
</tr>
<tr>
<td>Paris-Bichat</td>
<td>18 (12.9)</td>
<td>122 (87.1)</td>
<td>2.96 (1.42–6.15)</td>
<td>1.97 (0.69–5.67)</td>
</tr>
<tr>
<td><strong>Co-morbid conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>11 (26.2)</td>
<td>173 (31.7)</td>
<td>0.84 (0.40–1.75)</td>
<td>0.64</td>
</tr>
<tr>
<td>Renal failure</td>
<td>8 (19.0)</td>
<td>145 (26.6)</td>
<td>0.67 (0.30–1.51)</td>
<td>0.33</td>
</tr>
<tr>
<td>Solid cancer</td>
<td>7 (16.7)</td>
<td>167 (30.6)</td>
<td>0.48 (0.20–1.12)</td>
<td>0.09</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>4 (9.5)</td>
<td>13 (2.4)</td>
<td>2.48 (0.72–8.52)</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Presumed place of acquisition</strong></td>
<td>0.01</td>
<td>0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nosocomial</td>
<td>16 (38.1)</td>
<td>288 (52.8)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Healthcare-associated</td>
<td>4 (9.5)</td>
<td>89 (16.3)</td>
<td>0.71 (0.23–2.21)</td>
<td>0.99 (0.26–3.77)</td>
</tr>
<tr>
<td>Community</td>
<td>22 (52.4)</td>
<td>144 (26.4)</td>
<td>2.50 (1.24–5.04)</td>
<td>3.33 (1.31–8.48)</td>
</tr>
<tr>
<td><strong>Device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pacemaker</td>
<td>4 (6.4)</td>
<td>35 (9.5)</td>
<td>1.61 (0.50–5.14)</td>
<td>0.42</td>
</tr>
<tr>
<td>Prosthetic valve</td>
<td>10 (23.8)</td>
<td>28 (5.1)</td>
<td>5.3 (2.25–12.49)</td>
<td>0.0001</td>
</tr>
<tr>
<td><strong>Clinical features</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>89 (73.6)</td>
<td>395 (84.8)</td>
<td>1.84 (0.62–5.46)</td>
<td>0.27</td>
</tr>
<tr>
<td>Heart valve disease</td>
<td>18 (43.9)</td>
<td>107 (22.1)</td>
<td>5.17 (2.43–11.03)</td>
<td>0.0001</td>
</tr>
<tr>
<td><strong>Biological parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTP of first positive blood culture (h)</td>
<td>0.003</td>
<td>0.003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.28–9.9</td>
<td>17 (40.5)</td>
<td>131 (24.0)</td>
<td>2.28 (1.23–3.97)</td>
<td>2.53 (1.22–5.25)</td>
</tr>
<tr>
<td>10.0–13.7</td>
<td>11 (26.2)</td>
<td>136 (25.0)</td>
<td>1.23 (1.04–1.45)</td>
<td>1.22 (1.01–1.46)</td>
</tr>
<tr>
<td>13.8–18.0</td>
<td>6 (14.3)</td>
<td>140 (25.7)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Variables</td>
<td>Definite IE (n=42)</td>
<td>Others (n=545)</td>
<td>Univariate analysis</td>
<td>Multivariate analysis (n=477)</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>18.1–131.0</td>
<td>8 (19.0)</td>
<td>138 (25.3)</td>
<td>2.16 (0.81–5.74)</td>
<td>3.91 (1.26–12.11)</td>
</tr>
<tr>
<td>MRSA (n=585)</td>
<td>3 (7.1)</td>
<td>109 (20.1)</td>
<td>0.30 (0.09–1.02)</td>
<td>0.05</td>
</tr>
<tr>
<td>CRP (mg/L), per unit (n=534)</td>
<td>256 (150-302)</td>
<td>180 (102-282)</td>
<td>1.003 1.00–1.01)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Morphological data**

| Echocardiography (TTE and/or TEE) | 41 (97.6) | 352 (64.6) | 17.4 (2.32–130.34) | 0.005 0.00–95.28 | 11.07 (1.28–95.28) | 0.03 |

Categorical variables are presented as numbers (%). Non-normally distributed quantitative variables are reported as median (quartile 1 - quartile 3). Normally distributed quantitative variables are presented as mean ± standard deviation.

IE: infective endocarditis; OR: odds ratio; CI: confidence interval; TTP: time to positivity; MRSA: Methicillin resistant *Staphylococcus aureus*; CRP: C reactive protein.

308

309
Table 3. Risk factors for 30-day mortality in patients with *S. aureus* bacteraemia

<table>
<thead>
<tr>
<th>Variables</th>
<th>30-day mortality (n=121)</th>
<th>Survived (n=466)</th>
<th>Univariate analysis</th>
<th>Multivariate analysis (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>P</td>
<td>RR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y) per year</td>
<td>70.2 ± 14.8</td>
<td>63.6 ± 16.5</td>
<td>1.02 (1.01–1.04)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Female</td>
<td>37 (36.3)</td>
<td>111 (29.3)</td>
<td>1.22 (0.82–1.84)</td>
<td>0.36</td>
</tr>
<tr>
<td>Centre</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyon</td>
<td>61 (20.3)</td>
<td>240 (79.7)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Besançon</td>
<td>19 (17.9)</td>
<td>87 (82.1)</td>
<td>0.89 (0.53–1.49)</td>
<td>0.92</td>
</tr>
<tr>
<td>Nîmes</td>
<td>7 (17.5)</td>
<td>33 (82.5)</td>
<td>0.74 (0.34–1.62)</td>
<td>0.73</td>
</tr>
<tr>
<td>Paris-Bichat</td>
<td>34 (24.3)</td>
<td>106 (75.7)</td>
<td>1.26 (0.83–1.92)</td>
<td>1.29</td>
</tr>
<tr>
<td><strong>Co-morbid conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabet mellitus</td>
<td>41 (33.9)</td>
<td>143 (30.7)</td>
<td>0.99 (0.67–1.44)</td>
<td>0.94</td>
</tr>
<tr>
<td>Renal failure</td>
<td>38 (31.4)</td>
<td>115 (24.7)</td>
<td>1.15 (0.78–1.70)</td>
<td>0.48</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>29 (24.0)</td>
<td>78 (16.7)</td>
<td>1.68 (1.09–2.60)</td>
<td>0.02</td>
</tr>
<tr>
<td>Solid cancer</td>
<td>37 (30.6)</td>
<td>137 (29.4)</td>
<td>1.02 (0.69–1.50)</td>
<td>0.93</td>
</tr>
<tr>
<td>McCabe score (n=584)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>8 (6.7)</td>
<td>50 (10.8)</td>
<td>1</td>
<td>0.0009</td>
</tr>
<tr>
<td>2</td>
<td>36 (30.0)</td>
<td>196 (42.2)</td>
<td>0.69 (0.31–1.52)</td>
<td>0.83</td>
</tr>
<tr>
<td>3</td>
<td>40 (33.3)</td>
<td>160 (34.5)</td>
<td>0.94 (0.43–2.08)</td>
<td>1.15</td>
</tr>
<tr>
<td>4</td>
<td>36 (30.0)</td>
<td>58 (12.5)</td>
<td>1.93 (0.88–4.22)</td>
<td>2.34</td>
</tr>
<tr>
<td><strong>Clinical features</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>89 (73.6)</td>
<td>395 (84.8)</td>
<td>0.67 (0.44–1.01)</td>
<td>0.06</td>
</tr>
<tr>
<td>Stroke (n=554)</td>
<td>10 (9.1)</td>
<td>8 (1.8)</td>
<td>3.13 (1.60–6.14)</td>
<td>0.001</td>
</tr>
<tr>
<td>Embolus</td>
<td>3 (2.5)</td>
<td>12 (2.6)</td>
<td>0.98 (0.30–3.20)</td>
<td>0.97</td>
</tr>
<tr>
<td>Mitral</td>
<td>4 (6.6)</td>
<td>6 (1.8)</td>
<td>2.77 [0.99–7.75]</td>
<td>0.05</td>
</tr>
<tr>
<td>Source of infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Variables</th>
<th>30-day mortality (n=121)</th>
<th>Survived (n=466)</th>
<th>Univariate analysis</th>
<th>Multivariate analysis (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>P</td>
<td>RR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>12 (9.9)</td>
<td>30 (6.4)</td>
<td>1.52 (0.83–2.78)</td>
<td>0.18</td>
</tr>
<tr>
<td>Osteitis (n=555)</td>
<td>10 (9.0)</td>
<td>52 (11.7)</td>
<td>0.83 (0.43–1.60)</td>
<td>0.58</td>
</tr>
<tr>
<td>Arthritis (n=554)</td>
<td>7 (6.4)</td>
<td>56 (12.6)</td>
<td>0.53 (0.25–1.15)</td>
<td>0.11</td>
</tr>
<tr>
<td>SSSI (n=555)</td>
<td>30 (27.0)</td>
<td>156 (35.1)</td>
<td>0.73 (0.48–1.11)</td>
<td>0.14</td>
</tr>
<tr>
<td>Pneumonia (n=540)</td>
<td>26 (23.6)</td>
<td>47 (10.9)</td>
<td>2.05 (1.31–3.2)</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>1.69 (1.01–2.85)</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical site</td>
<td>5 (4.1)</td>
<td>66 (14.2)</td>
<td>0.32 [0.13–0.78]</td>
<td>0.01</td>
</tr>
</tbody>
</table>

**Biological parameters**

- **TTP of first positive blood culture (h)**
<table>
<thead>
<tr>
<th>RR (95% CI)</th>
<th>P</th>
<th>RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 13.7</td>
<td>47 (38.8)</td>
<td>245 (52.6)</td>
<td>1</td>
</tr>
<tr>
<td>≤ 13.7</td>
<td>74 (61.2)</td>
<td>221 (47.4)</td>
<td>1.51 (1.05–2.18)</td>
</tr>
</tbody>
</table>
- **MRSA (n=585)**
<table>
<thead>
<tr>
<th>RR (95% CI)</th>
<th>P</th>
<th>RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>36 (30.0)</td>
<td>76 (16.3)</td>
<td>1.25 (1.02–1.53)</td>
<td>0.03</td>
</tr>
<tr>
<td>1.92 (1.20–3.07)</td>
<td>0.006</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
- **CRP (mg/L)**
<table>
<thead>
<tr>
<th>RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 – 104</td>
<td>16 (12.1)</td>
</tr>
<tr>
<td>105 – 182</td>
<td>21 (15.4)</td>
</tr>
<tr>
<td>183 – 284</td>
<td>34 (25.6)</td>
</tr>
<tr>
<td>285 – 927</td>
<td>31 (23.3)</td>
</tr>
<tr>
<td>No data (n=53)</td>
<td>19 (35.8)</td>
</tr>
</tbody>
</table>

**Therapeutic parameters**

- **Antibiotic before blood culture (n=577)**
<table>
<thead>
<tr>
<th>RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 (6.9)</td>
<td>30 (6.5)</td>
</tr>
</tbody>
</table>
- **Appropriate empirical antibiotic**
<table>
<thead>
<tr>
<th>RR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>96 (79.3)</td>
<td>359 (77.0)</td>
</tr>
</tbody>
</table>
Categorical variables are presented as numbers (%). Non-normally distributed quantitative variables are reported as median (quartile 1 - quartile 3). Normally distributed quantitative variables are presented as mean ± standard deviation.

RR: relative risk; CI: confidence interval; SSSI: Skin and skin structure infection; TTP: time to positivity; MRSA: Methicillin resistant *Staphylococcus aureus*; CRP: C reactive protein

<table>
<thead>
<tr>
<th>Variables</th>
<th>30-day mortality (n=121)</th>
<th>Survived (n=466)</th>
<th>Univariate analysis (n=529)</th>
<th>Multivariate analysis (n=529)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (95% CI)</td>
<td>P</td>
<td>RR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Categorical</td>
<td>Median (Q1-Q3)</td>
<td></td>
<td>Median (Q1-Q3)</td>
<td></td>
</tr>
</tbody>
</table>

311

312
Figure Legends

Figure 1. Association between time to blood culture positivity, and i) infective endocarditis (Figure 1A), and ii) 30 day-mortality (Figure 1B), in patients with *Staphylococcus aureus* bacteraemia.

Figure 2. Association between time to blood culture positivity and infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: Second-degree fractional polynomial adjusted for covariates.

- X axis: Time to blood culture positivity in hours adjusted for covariates
- Y axis: Partial predictor + residual of infective endocarditis

Figure 3. *In vitro* study of *Staphylococcus aureus* isolates originating from patients with infective endocarditis.

- Strains originating from patients with short (first quartile), and long (fourth quartile) time-to-positivity (TTP), referred to as ‘early’, and ‘late’ strains, were tested.

Figure 3A. Doubling time calculated from the exponential growth phase data of triplicate cultures in BHI

Figure 3B. TTP in artificially inoculated aerobic and anaerobic blood cultures filled with human blood, with standardized inoculum.

Supplementary Figure 1: flow chart
Supplementary Table 1. Comparison of patients enrolled in this study, and the rest of the VIRSTA cohort

<table>
<thead>
<tr>
<th>Variables</th>
<th>Study population</th>
<th>Non-included patients</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=587)</td>
<td>(n=1421)</td>
<td></td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>65.3 ± 16.3</td>
<td>65.0 ± 17.5</td>
<td>0.76</td>
</tr>
<tr>
<td>Male</td>
<td>420 (71.6)</td>
<td>875 (61.6)</td>
<td>0.0001</td>
</tr>
<tr>
<td><strong>Co-morbid conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal failure</td>
<td>153 (26.1)</td>
<td>408 (28.7)</td>
<td>0.23</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>184 (31.4)</td>
<td>383 (27.0)</td>
<td>0.05</td>
</tr>
<tr>
<td>Heart failure</td>
<td>120 (20.4)</td>
<td>400 (28.2)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>17 (2.9)</td>
<td>46 (3.2)</td>
<td>0.69</td>
</tr>
<tr>
<td>Solid cancer</td>
<td>174 (29.6)</td>
<td>419 (29.5)</td>
<td>0.95</td>
</tr>
<tr>
<td>Immunocompromised status</td>
<td>123 (21.0)</td>
<td>229 (21.1)</td>
<td>0.50</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>107 (18.2)</td>
<td>171 (12.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>McCabe score</td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>1</td>
<td>58 (9.9)</td>
<td>113 (8.0)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>232 (39.7)</td>
<td>483 (34.0)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>200 (34.2)</td>
<td>550 (38.7)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>94 (16.1)</td>
<td>274 (19.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Presumed place of acquisition</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community-acquired</td>
<td>166 (28.3)</td>
<td>355 (25.0)</td>
<td>0.13</td>
</tr>
<tr>
<td>Healthcare-associated</td>
<td>93 (15.8)</td>
<td>260 (18.3)</td>
<td>0.19</td>
</tr>
<tr>
<td>Nosocomial</td>
<td>304 (51.8)</td>
<td>771 (54.3)</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Site of infection</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infective endocarditis</td>
<td>42 (7.2)</td>
<td>179 (12.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Osteitis</td>
<td>62 (11.2)</td>
<td>149 (10.5)</td>
<td>0.67</td>
</tr>
<tr>
<td>Arthritis</td>
<td>63 (11.4)</td>
<td>104 (7.3)</td>
<td>4.10⁻³</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>73 (13.5)</td>
<td>141 (10.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>Skin and skin structure infection</td>
<td>186 (33.5)</td>
<td>394 (27.8)</td>
<td>0.01</td>
</tr>
</tbody>
</table>
### Variables

<table>
<thead>
<tr>
<th>Study population (n=587)</th>
<th>Non-included patients (n=1421)</th>
<th><em>P</em>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urinary tract infection</strong></td>
<td>80 (14.4)</td>
<td>132 (9.4)</td>
</tr>
<tr>
<td><strong>Catheter related-infection</strong></td>
<td>173 (30.6)</td>
<td>315 (22.3)</td>
</tr>
</tbody>
</table>

#### Device

- **Pacemaker**
  - 39 (6.8) | 105 (7.3) | 0.71 |
- **Prosthetic valve**
  - 19 (3.2) | 53 (3.7) | 0.59 |
- **Vascular grafts**
  - 42 (7.4) | 114 (7.9) | 0.66 |
- **Prosthetic joint**
  - 70 (12.3) | 214 (14.9) | 0.69 |

#### Clinical features

- **Fever**
  - 472 (82.7) | 1302 (90.7) | <0.0001 |
- **Heart valve disease**
  - 125 (21.3) | 240 (16.9) | 0.02 |
- **Stroke**
  - 18 (3.2) | 57 (4.0) | 0.42 |
- **Embolus**
  - 15 (2.6) | 48 (3.4) | 0.34 |
- **Intensive care unit**
  - 165 (28.1) | 449 (31.6) | 0.25 |
- **All-cause death at day 30**
  - 121 (20.6) | 291 (20.5) | 0.95 |

#### Biological parameters

- **C reactive protein (mg/L)**
  - 182 (104-284) | 192 (115-280) | 0.29 |
- **Time to positivity (hours)**
  - 13.7 (9.9 - 18) | - | - |
- **MRSA**
  - 112 (19.2) | 268 (18.9) | 0.90 |

Categorical variables are presented as numbers (%). Non-normally distributed quantitative variables are reported as median (quartile 1 - quartile 3). Normally distributed quantitative variables are presented as mean ± standard deviation.

---

MRSA: Methicillin-resistant *Staphylococcus aureus*. Immunocompromised status: HIV, hematologic malignancy, immunosuppressive drugs
Supplementary Table 2. Factors associated with time to blood cultures positivity (TTP) in *Staphylococcus aureus* bacteraemia in univariate analysis

<table>
<thead>
<tr>
<th>Variables</th>
<th>TTP ≤ 13.7 h (n=295)</th>
<th>TTP &gt; 13.7 h (n=292)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.0 ± 15.7</td>
<td>64.6 ± 16.9</td>
<td>0.29</td>
</tr>
<tr>
<td>Male</td>
<td>205 (69.5)</td>
<td>215 (73.6)</td>
<td>0.27</td>
</tr>
<tr>
<td>Centre</td>
<td>0.70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Besançon</td>
<td>58 (19.7)</td>
<td>48 (16.4)</td>
<td></td>
</tr>
<tr>
<td>Lyon</td>
<td>146 (49.5)</td>
<td>155 (53.1)</td>
<td></td>
</tr>
<tr>
<td>Nîmes</td>
<td>19 (6.4)</td>
<td>21 (7.2)</td>
<td></td>
</tr>
<tr>
<td>Paris-Bichat</td>
<td>72 (24.4)</td>
<td>68 (23.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Co-morbid conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>57 (19.3)</td>
<td>50 (17.1)</td>
<td>0.49</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>92 (31.2)</td>
<td>92 (31.5)</td>
<td>0.93</td>
</tr>
<tr>
<td>Renal failure</td>
<td>89 (30.5)</td>
<td>64 (22.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Intravenous drug use</td>
<td>11 (3.7)</td>
<td>6 (2.0)</td>
<td>0.23</td>
</tr>
<tr>
<td>Solid cancer</td>
<td>95 (32.2)</td>
<td>79 (27.0)</td>
<td>0.17</td>
</tr>
<tr>
<td>Immunodepression</td>
<td>78 (26.4)</td>
<td>45 (15.4)</td>
<td>0.001</td>
</tr>
<tr>
<td>McCabe score (n=584)</td>
<td></td>
<td>0.009</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>23 (7.8)</td>
<td>35 (12.1)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>104 (35.4)</td>
<td>128 (44.1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>118 (40.1)</td>
<td>82 (28.3)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>49 (16.7)</td>
<td>45 (15.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Device</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central venous catheter (n=547)</td>
<td>30 (10.9)</td>
<td>8 (2.9)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Vascular grafts</td>
<td>22 (7.4)</td>
<td>21 (7.2)</td>
<td>0.90</td>
</tr>
<tr>
<td>Prosthetic joint</td>
<td>44 (14.9)</td>
<td>29 (9.9)</td>
<td>0.07</td>
</tr>
</tbody>
</table>
**Clinical features**

<table>
<thead>
<tr>
<th></th>
<th>Cases 1</th>
<th>Cases 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>255 (86.4)</td>
<td>229 (78.4)</td>
<td>0.01</td>
</tr>
<tr>
<td>Heart valve disease (n=525)</td>
<td>63 (24.7)</td>
<td>62 (23.0)</td>
<td>0.64</td>
</tr>
<tr>
<td>Stroke (n=554)</td>
<td>17 (6.0)</td>
<td>1 (0.4)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Emboli (n=551)</td>
<td>17 (6.1)</td>
<td>6 (0.7)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Site of infection**

<table>
<thead>
<tr>
<th></th>
<th>Cases 1</th>
<th>Cases 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infective endocarditis</td>
<td>28 (9.5)</td>
<td>14 (4.8)</td>
<td>0.03</td>
</tr>
<tr>
<td>Osteitis (n=555)</td>
<td>31 (11.0)</td>
<td>31 (11.4)</td>
<td>0.87</td>
</tr>
<tr>
<td>Pneumonia (n=540)</td>
<td>30 (10.9)</td>
<td>43 (16.2)</td>
<td>0.08</td>
</tr>
<tr>
<td>Catheter related-infection (n=565)</td>
<td>109 (37.8)</td>
<td>64 (23.1)</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

**Biological parameters**

<table>
<thead>
<tr>
<th></th>
<th>Cases 1</th>
<th>Cases 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/L) (n=534)</td>
<td>187 (110-283)</td>
<td>179 (101-288)</td>
<td>0.66</td>
</tr>
<tr>
<td>MRSA (n=585)</td>
<td>42 (14.3)</td>
<td>70 (24.0)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

**Treatment data**

<table>
<thead>
<tr>
<th></th>
<th>Cases 1</th>
<th>Cases 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics before first blood culture (n=577)</td>
<td>17 (5.9)</td>
<td>21 (7.3)</td>
<td>0.48</td>
</tr>
</tbody>
</table>

**Morphological parameters**

<table>
<thead>
<tr>
<th></th>
<th>Cases 1</th>
<th>Cases 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vegetations (n=393)</td>
<td>18 (9.1)</td>
<td>13 (6.7)</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Categorical variables are presented as numbers (%). Non-normally distributed quantitative variables are reported as median (quartile 1 - quartile 3). Normally distributed quantitative variables are presented as mean ± standard deviation. CRP, C Reactive Protein.
Supplementary Table 3. Clonal complex of the 13 isolates sampled from patients with infective endocarditis, and short (<10 h), or long (>18 h) time-to-positivity (TTP) of first blood culture

<table>
<thead>
<tr>
<th>CC-MLST</th>
<th>TTP &lt;10 h</th>
<th>TTP &gt; 18 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>CC88</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CC45</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>CC15</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CC101</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CC121</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>8</strong></td>
<td><strong>5</strong></td>
</tr>
</tbody>
</table>

Note. All isolates were meticillin-susceptible *Staphylococcus aureus*
Supplementary Figure 1. Flow chart

2252 patients screened

162 non-included patients:
- Age <18 years (n=42)
- Catheter-related bacteraemia (n=65)
- Pregnant women (n=3)
- Adult guardianship (n=24)
- Non-admitted patients (blood cultures sampled in emergency department or as outpatient), or refusal to participate in the study (n=28)

2091 patients included

83 patients excluded (definite infective endocarditis diagnosed in a non-participating center)

2008 included patients (VIRSTA study)

1421 patients non-included:
- TTP not available (n=1139)
- TTP not reliable (n=282)*

587 patients enrolled (Besançon, n=106; Lyon, n=301; Nîmes, n=40; Paris-Bichat, n=140)

* Time of incubation start not reliably collected
REFERENCES


Time to positivity in hours and diagnosis of infective endocarditis

No infective endocarditis (n=545)  Infective endocarditis (n=42)
Second-degree fractional polynomial (.5 .5), adjusted for covariates